Stockscreener 앱 받기
7.98
0.13%
0.01
시간 외 거래:
7.98
Vigil Neuroscience Inc 주식(VIGL)의 최신 뉴스
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Crown Electrokinetics Corp. (OTCCRKN), Elevation Oncology, Inc. (NasdaqELEV), Sitio Royalties Corp. (NYSESTR), Vigil Neuroscience, Inc. (NasdaqV - TradingView
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders - MarketScreener
Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet - MSN
Vigil Neuroscience: ALSP Data Doesn't Deliver, But Sanofi Purchase Remains Intact (VIGL) - Seeking Alpha
Vigil Neuroscience fails in mid-stage study for lead asset - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LSEA, FARO, TASK, VIGL on Behalf of Shareholders - marketscreener.com
Vigil Neuroscience halts Phase 2 trial for ALSP treatment By Investing.com - Investing.com South Africa
Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease - insights.citeline.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Flowserve Corporation (NYSE – FLS), Streamline Health Solutions, Inc. (Nasdaq – STRM), Sitio Royalties Corp. (NYSE – STR), Vigil Neuroscience, Inc. (Nasda - Morningstar
Hold Rating on Vigil Neuroscience Inc Amidst Acquisition and Trial Outcomes - TipRanks
VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the Firm - GuruFocus
Vigil Neuroscience (VIGL) Trial Results Impact Future Plans - GuruFocus
Vigil Neuroscience halts Phase 2 trial for ALSP treatment - Investing.com Australia
Vigil Neuroscience stock slips on trial setback (VIGL:NASDAQ) - Seeking Alpha
Vigil Neuroscience (VIGL) Updates on Iluzanebart in Phase 2 Trial | VIGL Stock News - GuruFocus
Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP - marketscreener.com
Clinical Setback: Vigil Neuroscience Halts Phase 2 ALSP Trial After Iluzanebart Shows No Efficacy - Stock Titan
Northern Trust Corp Has $110,000 Stock Position in Vigil Neuroscience, Inc. (NASDAQ:VIGL) - Defense World
Vigil Neuroscience (VIGL) Updates on Iluzanebart in Phase 2 Tria - GuruFocus
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger – PRA, AXL, SWTX and VIGL - GlobeNewswire Inc.
Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross? - sharewise
$HAREHOLDER NOTICE: The M&A Class Action Firm Continues To Investigate The MergerPRA, AXL, SWTX and VIGL - The Malaysian Reserve
HC Wainwright Has Bearish Estimate for VIGL FY2026 Earnings - Defense World
Sanofi to acquire Vigil Neuroscience in $470-M deal - MSN
Sanofi’s Acquisition Of Vigil Neuroscience - Global Legal Chronicle
Vigil Neuroscience (NASDAQ:VIGL) Downgraded by Stifel Nicolaus to Hold - Defense World
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update - The Globe and Mail
VIGL: Vigil Neuroscience's Rating Downgraded by Stifel | VIGL St - GuruFocus
VIGL: Vigil Neuroscience's Rating Downgraded by Stifel | VIGL Stock News - GuruFocus
France: Sanofi adding to neurology pipeline with acquisition of Vigil Neuroscience - Investors in Healthcare
Vigil Neuroscience (NASDAQ:VIGL) Downgraded by HC Wainwright to “Neutral” - Defense World
Stifel cuts Vigil Neuroscience stock rating, lowers target to $8 - Investing.com Australia
VIGL: HC Wainwright Downgrades Vigil Neuroscience, Lowers Price Target | VIGL Stock News - GuruFocus
Stifel cuts Vigil Neuroscience stock rating, lowers target to $8 By Investing.com - Investing.com India
Vigil Neuroscience (VIGL) Downgraded by Stifel Following Sanofi Deal | VIGL Stock News - GuruFocus
Vigil Neuroscience (VIGL) Downgraded Amid Acquisition Plans | VIGL Stock News - GuruFocus
Hold Rating on Vigil Neuroscience Amid Sanofi Acquisition and VG-3927 Developments - TipRanks
HC Wainwright Downgrades Vigil Neuroscience to Neutral From Buy, Price Target is $8 - marketscreener.com
Sanofi to Acquire Vigil Neuroscience for $470 Million to Access Experimental Alzheimer’s Drug Targeting TREM2 - geneonline.com
Wedbush Equities Analysts Reduce Earnings Estimates for VIGL - Defense World
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives $15.00 Consensus Price Target from Brokerages - Defense World
Vigil Neuroscience Elects Directors at Annual Meeting - MSN
Vigil Neuroscience (NASDAQ:VIGL) Rating Lowered to “Hold” at Mizuho - Defense World
Vigil Neuroscience (NASDAQ:VIGL) Cut to “Hold” at Guggenheim - Defense World
Vigil Neuroscience’s (VIGL) “Market Perform” Rating Reiterated at JMP Securities - Defense World
Sanofi to Acquire Vigil Neuroscience for Up to $600M in Alzheimer’s Drug Push - USA Herald
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Vigil Neuroscience, Inc. (NASDAQ: VIGL) - Financial Post
1.45%
0.86%
자본화:
|
볼륨(24시간):